The Guiding Principles on Access to Healthcare

Improving access to healthcare globally is a pressing societal challenge. Progress has been made, but we are faced with new challenges.

There is a need for continued innovation to address current and future unmet medical and healthcare needs. This requires new thinking and a comprehensive approach: All stakeholders of a healthcare system have to work together in seeking sustainable solutions that promote universal access to care.

The Guiding Principles on Access to Healthcare (GPAH) are a call to action to expand access to quality healthcare. They build on the experience and lessons learned by the industry from working with many stakeholders to help improve access to medicines and vaccines for areas as diverse as HIV/AIDS, neglected tropical diseases, and childhood immunization.

The GPAH recognize the importance of each of the following five core areas:

  • Collaboration
  • Research and development
  • Expanding availability of healthcare services
  • Developing health systems resources
  • Respecting human rights

The GPAH frame the signatories’ efforts—both as independent companies, and as a collective body of signatories—to reduce the global burden of disease by helping to ensure that medicines, vaccines, diagnostics, and other medical technology and assistance are effectively developed and deployed.

Download the Guiding Principles


The signatories view these Guiding Principles as an industry framework for developing individual, internal policies, procedures and practices on access to healthcare. These Guiding Principles do not create any rights in, or liability to, any person or organization, public or private.

All discussions within the BSR Healthcare Working Group forum—with regards to the Guiding Principles on Access to Healthcare and other items as well—will be conducted on an over arching industry-wide level in accordance with a pre-agreed agenda for each meeting and with strict adherence to any applicable competition laws. In particular, no strategic or forward looking-information that enables a participant to plan ahead accordingly or to coordinate commercial activities will be discussed or shared.


  • Astellas M
  • Bristol-Myers Squibb M
  • Eisai
  • Eli Lilly
  • GlaxoSmithKline M
  • Johnson & Johnson M
  • Merck (MSD) M
  • Merck Serono
  • Novartis M
  • Novo Nordisk M
  • Roche M
  • Sanofi M
  • Takeda M

A member of the BSR Healthcare Working Group.